UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)

UvA-DARE (Digital Academic Repository)

Monitoring illicit psychostimulants and related health issues

Brunt, T.M.

Link to publication

Citation for published version (APA):Brunt, T. M. (2012). Monitoring illicit psychostimulants and related health issues. Boxpress.

General rightsIt is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s),other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, statingyour reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Askthe Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam,The Netherlands. You will be contacted as soon as possible.

Download date: 03 Feb 2021

175

References

Aerts LA, Mallaret M, Rigter H (2000) N-methyl-1-(1,3-benzodioxol-5-yl)-2-

butanamine (MBDB): its properties and possible risks. Addict. Biol. 5,

269-282

Allott R, Paxton R, Leonard R. (1999). Drug education: a review of British

Government policy and evidence on effectiveness. Health Educ. Res.

14, 491-505

Ames B.N., Magaw R., Gold L.S. Ranking possible carcinogenic hazards.

Science 1987; 236: 271-280.

van Amsterdam JG, Best W, Opperhuizen A, de Wolff FA. (2004).

Evaluation of a procedure to assess the adverse effects of illicit

drugs. Regul. Toxicol. Pharmacol. 39(1), 1-4

van Amsterdam, J., Opperhuizen, A., Koeter, M., & van den Brink, W.

(2010). Ranking the harm of alcohol, tobacco and illicit drugs for the

individual and the population. European Addiction Research 16(4),

202-207.

Ansah T.A., Wade L.H., Shockley D.C. (1993). Effects of calcium channel

entry blockers on cocaine and amphetamine-induced motor activities

and toxicities. Life Sci. 53, 1947-1956

Antia U, Lee HS, Kydd RR, Tingle MD, Russell BR. (2009)

Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in

healthy human participants. Forensic Sci. Int. 186, 63-67

Apostolakos M.J., Varon M.E. (1996). Antiarrhythmic and anti-ischemic

properties of calcium-channel antagonists. New Horiz. 4, 45-57.

Asbridge, M., & Weerasinghe, S. (2009). Homicide in Chicago from 1890 to

1930: prohibition and its impact on alcohol- and non-alcohol-related

homicides. Addiction 104(3), 355-364.

Asia and Pacific Amphetamine-Type Stimulants Information Centre

(APAIC). (2010). http://www.apaic.org/

Baumann MH, Wang X, Rothman RB. (2007). 3,4-

Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a

reappraisal of past and present findings. Psychopharmacology (Berl)

189(4), 407-424

176

Baumgarten HG, Lachenmayer L. (2004). Serotonin neurotoxins-past and

present. Neurotox. Res. 6(7-8), 589-614

Baylen, CA, Rosenberg, H (2006) A review of the acute subjective effects

of MDMA/ecstasy. Addiction 101, 933-947.

BBC news (2009) Police warning over 'bubble' drug. Available at:

http://news.bbc.co.uk/2/hi/uk_news/england/tees/8370130.stm.

Becker J, Neis P, Röhrich J, Zörntlein S (2003) A fatal

paramethoxymethamphetamine intoxication. Leg Med (Tokyo) 5,

S138-141

Belhadj-Tahar, H, Sadeg, N. (2005). Methcathinone: a new postindustrial

drug. Forensic Sci. Int. 153, 99-101.

Behrman, A.D. (2008). Luck of the draw: common adulterants found in illicit

drugs. J Emerg Nurs 34, 80-82.

Benschop, A., Rabes, M., & Korf, D.J. (2002). Pill Testing, Ecstasy &

Prevention. Rozenberg, Amsterdam, The Netherlands.

Bertol, E., Trignano, C., Di Milia, M.G., Di, P.M., Mari, F. (2008). Cocaine-

related deaths: an enigma still under investigation. Forensic Sci. Int.

176, 121-123.

Blanken P, Hendriks VM, van Ree JM, van den Brink W. (2010). Outcome

of long-term heroin-assisted treatment offered to chronic, treatment-

resistant heroin addicts in the Netherlands. Addiction 105(2), 300-

308

Boer, de, D, Bosman IJ, Hidvégi E, Manzoni C, Benkö AA, dos Reys LJ,

Maes RA. (2001). Piperazine-like compounds: a new group of

designer drugs-of-abuse on the European market. Forensic Sci. Int.

121, 47-56

ter Bogt, T. (1997). One two three four... popmuziek, jeugdcultuur en stijl.

Boom Juridisch, Amsterdam

Bossong, M., Brunt, T.M., Van Dijk, J.P., Rigter, S., Hoek, J., Goldschmidt

,H., & Niesink, R.J. (2010). mCPP: an undesired addition to the

ecstasy market. Journal of Psychopharmacology 24(9), 1395-1401

Bossong MG, Van Dijk JP, Niesink RJ. (2005). Methylone and mCPP, two

new drugs of abuse? Addict Biol. 10, 321-3

177

Boyer EW, Quang L, Woolf A, Shannon M, Magnani B. (2001).

Dextromethorphan and ecstasy pills. JAMA 285, 409-410

Braida D, Zani A, Capurro V, Rossoni G, Pegorini S, Gori E, Sala M.

(2008). Diazepam protects against the enhanced toxicity of cocaine

adulterated with atropine. J. Pharmacol. Sci. 107, 408-418

Brandt SD, Sumnall HR, Measham F, Cole J. (2010a). Second generation

mephedrone. The confusing case of NRG-1. BMJ. 341, c3564

Brandt SD, Sumnall HR, Measham F, Cole J. (2010b). Analyses of second-

generation „legal-highs‟ in the UK: Initial findings. Drug Test. Anal.

2(8), 377-382

Brittebo E.B. (1987).Metabolic activation of phenacetin in rat nasal

mucosa: dose-dependent binding to the glands of Bowman. Cancer

Res. 47, 1449-1456

Brownstein, H.H., Taylor, B.G. (2007). Measuring the stability of illicit drug

markets: why does it matter? Drug Alcohol Dependence. 90 Suppl 1,

S52-S60.

Brunt, T.M., Rigter, S., Hoek, J., Vogels, N., van, D.P., Niesink, R.J.

(2009). An analysis of cocaine powder in the Netherlands: content

and health hazards due to adulterants. Addiction 104, 798-805.

Brunt TM, Poortman A, Niesink RJ, van den Brink W. (2011). Instability of

the ecstasy market and a new kid on the block: mephedrone. J.

Psychopharmacology 25(11), 1543-1547

Brunt TM, van Laar M, Niesink RJM, van den Brink W. (2010). The

relationship of quality and price of the psychostimulants cocaine and

amphetamine with health care outcomes. Drug Alcohol Dependence

111(1-2), 21-29

Buisman W. et al. (Eds.). (2000). Handboek Verslaving: hulpverlening,

preventie en beleid. (Vol. C-3130, pp.1-24). Houten, Bohn Stafleu &

Van Loghum

Butler GK, Montgomery AM. (2004). Impulsivity, risk taking and

recreational 'ecstasy' (MDMA) use. Drug Alcohol Dependence.

76(1), 55-62

Butler RA, Sheridan JL (2007) Highs and lows: patterns of use, positive

and negative effects of benzylpiperazine-containing party pills

178

(BZP-party pills) amongst young people in New Zealand. Harm

Reduct. J. 4, 18

Buttner A., Mall G., Penning R., Sachs H., Weis S. (2003). The

neuropathology of cocaine abuse. Leg Med (Tokyo) 5 Suppl 1,

S240-S242.

Bytzer P, Hallas J. (2000). Drug-induced symptoms of functional dyspepsia

and nausea. A symmetry analysis of one million prescriptions.

Aliment. Pharmacol. Ther. 14, 1479-1484

Caldicott DG, Edwards NA, Kruys A, Kirkbride KP, Sims DN, Byard RW,

Prior M, Irvine RJ. (2003). Dancing with "death": p-

methoxyamphetamine overdose and its acute management. J.

Toxicol. Clin. Toxicol. 41, 143-154

Calkins, RF, Aktan, GB, Hussain, KL (1995) Methcathinone: the next illicit

stimulant epidemic? J. Psychoactive Drugs 27, 277-285

Callaghan PD, Irvine RJ, Daws LC. (2005). Differences in the in vivo

dynamics of neurotransmitter release and serotonin uptake after

acute para-methoxyamphetamine and 3,4-

methylenedioxymethamphetamine revealed by

chronoamperometry. Neurochem. Int. 47, 350-361

Callaghan, R.C., Cunningham, J.K., Victor, J.C., & Liu, L.M. (2009). Impact

of Canadian federal methamphetamine precursor and essential

chemical regulations on methamphetamine-related acute-care

hospital admissions. Drug and Alcohol Dependence, 105(3), 185-193

Camilleri AM, Caldicott D (2005) Underground pill testing, down under.

Forensic Sci. Int. 151, 53-58

Carhart-Harris RL, King LA, Nutt DJ. (2011). A web-based survey on

mephedrone. Drug Alcohol Dependence

doi:10.1016/j.drugalcdep.2011.02.011

Caulkins, J.P., & Reuter, P. (1997). Setting goals for drug policy: harm

reduction or use reduction? Addiction 92(9), 1143-1150

Caulkins, J.P. (2001). Drug prices and emergency department mentions for

cocaine and heroin. Am. J. Public Health 91, 1446-1448

Caulkins, J.P. (2007). Price and purity analysis for illicit drug: data and

conceptual issues. Drug Alcohol Dependence 90 Suppl 1, S61-S68

179

Chiaia AC, Banta-Green C, Field J. (2008). Eliminating solid phase

extraction with large-volume injection LC/MS/MS: analysis of illicit

and legal drugs and human urine indicators in U.S. wastewaters.

Environ. Sci. Technol. 42(23), 8841-8848

Cohen BM, Butler R. (2010). BZP-party pills: a review of research on

benzylpiperazine as a recreational drug. Int. J. Drug Policy 22, 95-

101

Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA. (2002). The

content of ecstasy tablets: implications for the study of their long-

term effects. Addiction 97, 1531-1536

Cole, J.C., Goudie, A.J., Field, M., Loverseed, A.C., Charlton, S., &

Sumnall, H.R. (2008). The effects of perceived quality on the

behavioural economics of alcohol, amphetamine, cannabis, cocaine,

and ecstasy purchases. Drug and Alcohol Dependence 94(1-3), 183-

190

Compas, B., Hinden, B.R. & Gerhardt, C.A. (1995). Adolescent

development: Pathways of risk and resilience. Ann. Rev. Psychology

46, 265–293

Costa Storti C., De Grauwe P. (2009). Globalization and the price decline

of illicit drugs. Int. J. Drug Policy 20, 48-61

Cozzi, NV, Foley, KF. (2003). Methcathinone is a substrate for the

serotonin uptake transporter. Pharmacol. Toxicol. 93, 219-225.

Cuijpers P, Jonkers R, de Ja W. (2002). The effects of drug abuse

prevention at school: the 'Healthy School and Drugs' project.

Addiction 97(1), 67-73.

Cunningham, J.K., & Liu, L.M. (2003). Impacts of federal ephedrine and

pseudoephedrine regulations on methamphetamine-related hospital

admissions. Addiction 98(9), 1229-1237

Cunningham ,J.K., & Liu, L.M. (2005). Impacts of federal precursor

chemical regulations on methamphetamine arrests. Addiction 100(4),

479-488

Cunningham, J.K., Liu, L.M., & Muramoto, M. (2008). Methamphetamine

suppression and route of administration: precursor regulation impacts

180

on snorting, smoking, swallowing and injecting. Addiction 103(7),

1174-1186

Cunningham RS. (1997). 5-HT3-receptor antagonists: a review of

pharmacology and clinical efficacy. Oncol. Nurs. Forum 24, 33-40

Dal Cason, TA, Young, R, Glennon, RA. (1997). Cathinone: an

investigation of several N-alkyl and methylenedioxy-substituted

analogs. Pharmacol. Biochem. Behav. 58: 1109-1116

Dams R, De Letter EA, Mortier KA, Cordonnier JA, Lambert WE, Piette

MH, Van Calenbergh S, De Leenheer AP. (2003). Fatality due to

combined use of the designer drugs MDMA and PMA: a distribution

study J. Anal. Toxicol. 27(5), 318-322

Dancesafe. (2010). http://www.ecstasydata.org/stats.php

Darke, S., Kaye, S., Topp, L. (2002). Cocaine use in New South Wales,

Australia, 1996-2000: 5 year monitoring of trends in price, purity,

availability and use from the illicit drug reporting system. Drug

Alcohol Dependence 67, 81-88

Dave, D. (2006). The effects of cocaine and heroin price on drug-related

emergency department visits. J. Health Econ. 25, 311-333

Degenhardt, L., Roxburgh, A., Black, E., Bruno, R., Campbell, G., Kinner,

S., Fetherston, J. (2008). The epidemiology of methamphetamine

use and harm in Australia. Drug Alcohol Rev. 27, 243-252

Derzon J.H. & Lipsey M.W. (2002). A meta-analysis of the effectiveness of

mass-communication for changing substance-use knowledge,

attitudes and behavior. Mass Media and Drug Prevention: Classic

and Contemporary Theories and Research. Matwah, Lawrence

Erlbaum Associates Publishers, New Jersey, 231-258

Dick, D, Torrance, C. (2010). MixMag Drugs Survey. Mix Mag 225, 44-53

Ding X., Kaminsky L.S. (2003). Human extrahepatic cytochromes P450:

function in xenobiotic metabolism and tissue-selective chemical

toxicity in the respiratory and gastrointestinal tracts. Annu. Rev.

Pharmacol. Toxicol. 43, 149-73

Docherty JR, Green AR. (2010). The role of monoamines in the changes in

body temperature induced by 3,4-methylenedioxymethamphetamine

181

(MDMA, ecstasy) and its derivatives. Br. J. Pharmacol. 160(5), 1029-

1044

Doekhie, J., Nabben, T., Korf, D. (2009). Trendwatch 2008-2009.

Rozenberg Publishers, Amsterdam

Dughiero G, Schifano F, Forza G. (2001). Personality dimensions and

psychopathological profiles of Ecstasy users. Hum.

Psychopharmacology 16(8), 635-639

Dumont GJ, Verkes RJ. (2006). A review of acute effects of 3,4-

methylenedioxymethamphetamine in healthy volunteers. J.

Psychopharmacology 20, 176-187

Edeleano L. (1887). Über einige derivative der Phenylmethacrylsaure und

der Phenylisobuttersaure. Berl. Dtsch. Chem. Ges. 20, 616-622.

Edwards, G. (2001). Time-series analysis as an important contemporary

statistical tool. Addiction 96(7), 941-942

El-Mallakh RS, Abraham HD. (2007). MDMA (Ecstasy). Ann. Clin.

Psychiatry. 19(1), 45-52

Epstein D.H., Preston K.L., Stewart J., Shaham Y. (2006). Toward a model

of drug relapse: an assessment of the validity of the reinstatement

procedure. Psychopharmacology (Berl) 189, 1-16

Erowid. (2006). Erowid 4-Fluoroamphetamine (para-Fluoroamphetamine)

Vault, http://www.erowid.org/chemicals/4_fluoroamphetamine/

Erowid. (2010a). LSD. http://www.erowid.org/chemicals/

lsd/lsd_article3.shtml

Erowid. (2010b). Erowid Experience Vaults: 4-Methylmethcathinone

Reports, http://www.erowid.org/experiences/subs/

exp_4Methylmethcathinone.shtml

Europol. (2007). Amphetamine-type Stimulants in the European Union

1998-2007. Te Hague, The Netherlands,

http://www.europol.europa.eu/publications/

Serious_Crime_Overviews/EuropolUNGASSAssessment.PDF

EMCDDA (2003-2011) European information system and database on new

drugs, EWS final reports 2003-2011, http://ednd.emcdda.europa.eu/

EMCDDA. (2008). Annual Report 2008. http://www.emcdda.europa.eu/

attachements.cfm/ att_64227_EN_EMCDDA_AR08_en.pdf.

182

EMCDDA. (2007). Annual Report 2007. http://www.emcdda.europa.eu/

html.cfm/ index44682EN.html

EMCDDA. (2010). Annual Report 2010. http://www.emcdda.europa.eu/

attachements.cfm/ att_120104_EN_EMCDDA_AR2010_EN.pdf

EMCDDA. (2007). Cocaine and crack cocaine: a growing public health

issue.

http://www.emcdda.europa.eu/attachements.cfm/att_44748_EN_TDS

I07002ENC.pdf

EMCDDA. (2009). Annual Report 2009. http://www.emcdda.europa.eu/

attachements.cfm/ att_93236_EN_EMCDDA_AR2009_EN.pdf

EMCDDA. (2010). EMCDDA and Europol step up information collection on

mephedrone. Available at: http://www.emcdda.europa.eu/

publications/drugnet/online/2010/69/article3

EMCDDA. (2010). National reports 2005-2009.

http://www.emcdda.europa.eu/publications

EMCDDA. (2010). Statistical bulletins 2004-2009.

http://www.emcdda.europa.eu/stats/archive

EMCDDA. (2010). EWS final reports 2004 – 2009.

http://ednd.emcdda.europa.eu/

Europol-EMCDDA. (2010). Annual Report on the implementation of

Council Decision 2005/387/JHA,http://www.emcdda.europa.eu/

attachements.cfm/att_132857_EN_EMCDDA-

Europol%20Annual%20Report%202010A.pdf

EMCDDA. (2011). Report on the risk assessment of mephedrone in the

framework of the Council Decisionon new psychoactive substances.

http://www.emcdda.europa.eu/attachements.cfm/att_116646_EN_T

DAK11001ENC_WEB-OPTIMISED%20FILE.pdf

Evans-Brown M, Bellis MA, McVeigh J. (2011). Should "legal highs" be

regulated as medicinal products? BMJ. 342, d1101

Falck RS, Carlson RG, Wang J, Siegal HA. (2004). Sources of information

about MDMA (ecstasy): perceived accuracy, importance, and

implications for prevention among young adult users. Drug Alcohol

Dependence 74(1), 45-54

183

Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC. (1998). Recent

paramethoxyamphetamine deaths. J. Anal. Toxicol. 22(2), 169-172

Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, Rao ML.

(2004). Pharmacokinetics of m-chlorophenylpiperazine after

intravenous and oral administration in healthy male volunteers:

implication for the pharmacodynamic profile. Pharmacopsychiatry

37, 180-188

Fischer JF, Cho AK. (1979). Chemical release of dopamine from striatal

homogenates: evidence for an exchange diffusion model. J.

Pharmacol. Exp. Ther. 1979 208(2), 203-209

Fleckenstein AE, Gibb JW, Hanson GR. (2000). Differential effects of

stimulants on monoaminergic transporters: pharmacological

consequences and implications for neurotoxicity. Eur. J. Pharmacol.

406(1), 1-13

Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. (2007). New

insights into the mechanism of action of amphetamines. Annu. Rev.

Pharmacol. Toxicol. 47, 681-698

Florin SM, Kuczenski R, Segal DS. (1994). Regional extracellular

norepinephrine responses to amphetamine and cocaine and effects

of clonidine pretreatment. Brain Res. 654(1), 53-62

Foltin R.W., Fischman M.W., Levin F.R. (1995). Cardiovascular effects of

cocaine in humans: laboratory studies. Drug Alcohol Dependence 37,

193-210

Frishman W.H., Del Vecchio A., Sanal S., Ismail A. (2003). Cardiovascular

manifestations of substance abuse part 1: cocaine. Heart Dis. 5, 187-

201

Fry E, Levi J. (2009). Pharmacology and Abuse of Cocaine,

Amphetamines, Ecstasy and Related Designer Drugs. Springer-

Verlag, New York

Fucci N., De Giovanni N. (1998). Adulterants encountered in the illicit

cocaine market. Forensic Sci. Int. 95, 247-252

Fucci N. (2007). Unusual adulterants in cocaine seized on Italian

clandestine market. Forensic Sci. Int. 172, e1

184

Galbis-Reig D. (2004). Sigmund Freud, MD: Forgotten Contributions to

Neurology, Neuropathology, and Anesthesia. Internet Journal of

Neurology 3(1)

Gamma A, Jerome L, Liechti ME, Sumnall HR. (2005). Is ecstasy

perceived to be safe? A critical survey. Drug Alcohol Dependence

77, 185-193

Gelper, S., Croux, C. (2006). Multivariate out-of-sample tests for Granger

causality. Comp. Stat. Dat. Anal. 51, 3319-3329

Gijsman HJ, Cohen AF, van Gerven JM. (2004). The application of the

principles of clinical drug development to pharmacological

challenge tests of the serotonergic system. J. Psychopharmacology

18, 7-13

Gilmour, S., Degenhardt, L., Hall, W., & Day, C. (2006). Using intervention

time series analyses to assess the effects of imperfectly identifiable

natural events: a general method and example. BMC Medical

Research Methodology 6, 16.

Giraudon I, Bello PY. (2007). Monitoring ecstasy content in France: results

from the National Surveillance System 1999-2004. Subst. Use

Misuse 42, 1567-1578

Glauser, J., Queen, J.R. (2007). An overview of non-cardiac cocaine

toxicity. J. Emerg. Med. 32, 181-186

Glennon RA, Ismaiel AE, McCarthy BG, Peroutka SJ. (1989). Binding of

arylpiperazines to 5-HT3 serotonin receptors: results of a structure-

affinity study. Eur. J. Pharmacol. 168, 387-392

Gold MS. (1993). Cocaine. Plenum Medical Book Co, New York

Goldschmidt HMJ. (2004). The NEXUS vision. An alternative to the

reference value concept. Clin. Chem. Lab. Med. 42, 868-873

Goldstone, MS. (1993). 'Cat': methcathinone--a new drug of abuse. JAMA

269, 2508

Goudie, A.J., Sumnall, H.R., Field, M., Clayton, H., & Cole, J.C. (2007).

The effects of price and perceived quality on the behavioural

economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy

purchases. Drug and Alcohol Dependence 89(2-3), 107-115

185

Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA,

Lindenblatt H, Hermle L, Spitzer M, Sass H. (1999).

Psychopathological, neuroendocrine and autonomic effects of 3,4-

methylenedioxyethylamphetamine (MDE), psilocybin and d-

methamphetamine in healthy volunteers. Results of an

experimental double-blind placebo-controlled study.

Psychopharmacology (Berl) 142, 41-50

Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S,

Kunert HJ, Fimm B, Sass H. (2000). Impaired cognitive performance

in drug free users of recreational ecstasy (MDMA). J. Neurol.

Neurosurg. Psychiatry 68, 719-725

Gouzoulis-Mayfrank, E., & Daumann, J. (2006). The confounding problem

of polydrug use in recreational ecstasy/MDMA users: a brief

overview. J. Psychopharmacology 20(2), 188-193

Gouzoulis-Mayfrank E, Daumann J. (2006). Neurotoxicity of

methylenedioxyamphetamines (MDMA; ecstasy) in humans: how

strong is the evidence for persistent brain damage? Addiction 101(3),

348-361

Grov, C., Kelly, B.C., & Parsons, J.T. (2009). Polydrug use among club-

going young adults recruited through time-space sampling.

Substance Use and Misuse 44(6), 848-864

Gu J., Cui H., Behr M., Zhang L., Zhang Q.Y., Yang W. et al. (2005). In

vivo mechanisms of tissue-selective drug toxicity: effects of liver-

specific knockout of the NADPH-cytochrome P450 reductase gene on

acetaminophen toxicity in kidney, lung, and nasal mucosa. Mol.

Pharmacol. 67, 623-30

Gyermek L. (1998). Pharmacology of Antimuscarinic Agents. Kane H,

editor. Pharmacology and toxicology: basic and clinical aspect series.

Hollinger, M. A, editor. Boca Raton, Florida: CRC Press p. 1-477

Gygi, MP, Gibb, JW, Hanson, GR. (1996). Methcathinone: an initial study

of its effects on monoaminergic systems. J. Pharmacol. Exp. Ther.

276, 1066-1072

Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC,

Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM,

186

Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.

(2011). 4-Methylmethcathinone(mephedrone): neuropharmacological

effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther.

DOI:10.1124/ jpet.111.184119

Hartgers C, Buning EC, van Santen GW, Verster AD & Coutinho RA.

(1989). The impact of the needle and syringe-exchange programme

in Amsterdam on injecting risk behaviour. AIDS 3, 571-576.

Hatzidimitriou G, McCann UD, Ricaurte GA. (1999). Altered serotonin

innervation patterns in the forebrain of monkeys treated with (+/-)3,4-

methylenedioxymethamphetamine seven years previously: factors

influencing abnormal recovery. J. Neurosci. 19(12), 5096-5107

Hegadoren KM, Baker GB, Bourin M. (1999). 3,4-Methylenedioxy

analogues of amphetamine: defining the risks to humans. Neurosci.

Biobehav. Rev. 23, 539-553

Helmlin H. (2010). http://www.erowid.org/psychoactives/testing/

testing_article2.shtml

Henderson, LA, Glass, WJ. (1994). LSD: Still with Us after All These

Years. Wiley & Sons, John Incorporated, San Fransisco, CA

Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. (1993).

Psychological effects of MDE in normal subjects. Are entactogens a

new class of psychoactive agents? Neuropsychopharmacology 8,

171-176

Herttua, K., Mäkelä, P., & Martikainen, P. (2008). Changes in alcohol-

related mortality and its socioeconomic differences after a large

reduction in alcohol prices: a natural experiment based on register

data. Am. J. of Epidemiology, 168(10), 1110-1118

Higgins GA, Kilpatrick GJ. (1999). 5-HT(3) receptor antagonists. Expert.

Opin. Investig. Drugs 8, 2183-2188

Hinson J.A. (1983). Reactive metabolites of phenacetin and

acetaminophen: a review. Environ. Health Perspect. 49, 71-79

Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. (2009).

Effectiveness of prokinetic agents against diseases external to the

gastrointestinal tract. J. Gastroenterol. Hepatol. 24, 537-546

187

Horowitz B.Z., Panacek E.A., Jouriles N.J. (1997). Severe rhabdomyolysis

with renal failure after intranasal cocaine use. J. Emerg. Med. 15,

833-837

Hosmer DW, Lemeshow S. (2000). Applied logistic regression Second

Edition. Wiley, University of Massachusetts Amherst,

Massachusetts

Huerta-Fontela M. et al. (2007). Ultraperformance liquid chromatography-

tandem mass spectrometry analysis of stimulatory drugs of abuse in

wastewater and surface waters. Anal. Chem. 79, 3921-3829

Hummel M, Unterwald EM. (2002). D1 dopamine receptor: a putative

neurochemical and behavioral link to cocaine action. J. Cell Physiol.

191(1), 17-27

Huxster, JK, Pirona, A, Morgan, MJ. (2006). The sub-acute effects of

recreational ecstasy (MDMA) use: a controlled study in humans. J.

Psychopharmacology 20, 281-290

Hyatt, R.R., Jr., Rhodes, W. (1995). The price and purity of cocaine: the

relationship to emergency room visits and death, and to drug use

among arrestees. Stat. Med. 14, 655-668

Jaehne EJ, Salem A, Irvine RJ. Pharmacological and behavioral

derterminants of cocaine, methamphetamine, 3,4-

methylenedioxymethamphetamine, and para-methoxyamphetamine-

induced hyperthermia. Psychopharmacology (Berl) 194(1), 41-52

Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, Russell BR (2010)

Determining the subjective effects of TFMPP in human males.

Psychopharmacology Berl 211, 347-353

Jeffrey W. Colour Tests. In: Moffat A.C, Osselton M.D., Widdop B., editors.

(2003). Clarke's Analysis of Drugs and Poisons, Third Edition. 3 ed.

London: Pharmaceutical Press p. 279-300.

Jerrard, DA. (1990). "Designer drugs"--a current perspective. J. Emerg.

Med. 8, 733-741.

Johnston, J., Barratt, M.J., Fry, C.L., Kinner, S., Stoové, M., Degenhardt,

L., George, J., Jenkinson, R., Dunn, M. & Bruno, R. (2006). A survey

of regular ecstasy users‟ knowledge and practices around

188

determining pill content and purity: Implications for policy and

practice. Int. J. Drug Policy 17, 464-472

Johnstone AC, Lea RA, Brennan KA, Schenk S, Kennedy MA, Fitzmaurice

PS. (2007). Benzylpiperazine: a drug of abuse? J.

Psychopharmacology 21, 888-894

Johansen, S. (1996). Likelihood-Based Inference in Cointegrated Vector

Autoregressive Models. 1st ed. Oxford University Press, Oxford,

United Kingdom.

Johansen SS, Hansen AC, Müller IB, Lundemose JB, Franzmann MB.

(2003). Three fatal cases of PMA and PMMA poisoning in Denmark.

J. Anal. Toxicol. 27, 253-256

Jones S, Kauer JA. (1999). Amphetamine depresses excitatory synaptic

transmission via serotonin receptors in the ventral tegmental area. J.

Neurosci. 19(22), 9780-9787

Kalasinsky KS, Hugel J, Kish SJ. (2004). Use of MDA (the "love drug") and

methamphetamine in Toronto by unsuspecting users of ecstasy

(MDMA). J. Forensic Sci. 49, 1106-1112

Kasprzyk-Hordern, B. Dinsdale, R.M. & Guwy, A.J. (2008). Multiresidue

methods for the analysis of pharmaceuticals, personal care products

and illicit drugs in surface water and wastewater by solid-phase

extraction and ultra performance liquid chromatography-electrospray

tandem mass spectrometry. Anal. Bioanal. Chem. 391, 1293-1308

Katz N et al. (2010). Usefulness of prescription monitoring programs for

surveillance: analysis of Schedule II opioid prescription data in

Massachusetts, 1996–2006 Pharmacoepidemiol. Drug Safety 19,

115-123

Kelly JP. (2011). Cathinone derivatives: A review of their chemistry,

pharmacology and toxicology. Drug Test. Anal. 3(7-8), 439-453

Keijsers L., Bossong M G, Waarlo A.J. (2007). Participatory evaluation of a

Dutch warning campaign for substance-users. Health Risk Soc. 10,

283-295.

Kenyon SL, Ramsey JD, Lee T, Johnston A, Holt DW. (2005). Analysis for

identification in amnesty bin samples from dance venues. Ther.

Drug Monit. 27, 793-798

189

Kerr T, Small W, Moore D, Wood E. (2007). A micro-environmental

intervention to reduce the harms associated with drug-related

overdose: evidence from the evaluation of Vancouver's safer

injection facility. Int. J. Drug Policy 18(1), 37-45

King LA. (2009). Forensic Chemistry of Substance Misuse: A Guide to

Drug Control. Royal Society of Chemistry, Cambridge, UK

Kita T, Miyazaki I, Asanuma M, Takeshima M, Wagner GC. (2009).

Dopamine-induced behavioral changes and oxidative stress in

methamphetamine-induced neurotoxicity. Int. Rev. Neurobiol. 88,

43-64

Knuepfer, M.M. (2003). Cardiovascular disorders associated with cocaine

use: myths and truths. Pharmacol. Ther. 97, 181-222.

Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA.

(2008). Physiological and subjective responses to controlled oral

3,4-methylenedioxymethamphetamine administration. J. Clin.

Psychopharmacology 28, 432-440

Konijn K, Pennings E, De Wolff F. (1997). XTC: Klinische en

Toxicologische Aspecten. LUMC, Leiden

Korf, D.J., Benschop, A., & Brunt, T.M. (2003). Pill testing in The

Netherlands. Rozenberg, Amsterdam, The Netherlands.

de Kort, M. & Cramer, T. (1999). Pragmatism versus ideology: Dutch drug

policy Journal of Drug Issues 29, 473–492.

Koski, A., Sirén, R., Vuori, E., & Poikolainen, K. (2007). Alcohol tax cuts

and increase in alcohol-positive sudden deaths: a time-series

intervention analysis. Addiction 102(3), 362-368

Kraner JC, McCoy DJ, Evans MA, Evans LE, Sweeney BJ. (2001).

Fatalities caused by the MDMA-related drug

paramethoxyamphetamine (PMA). J. Anal. Toxicol. 25, 645-648

Kriener H et al. (2001). An inventory of on-site pill-testing interventions in

the European Union. Vienna Social Projects. EMCDDA, Lisbon

Laar, van, M.W., Cruts, A.A.N., Verdurmen, J.E.E., van Ooyen-Houben,

M.M.J., Meijer, R.F., (2008). The Netherlands National Drug Monitor:

Annual Report 2007. Trimbos Institute, Utrecht.

190

Laar, van, M.W., Cruts, A.A.N., van Ooyen-Houben, M.M.J., Meijer, R.F., &

Brunt T.M. (2010). The Netherlands National Drug Monitor: Annual

Report 2009. Trimbos Institute, Utrecht, The Netherlands.

Laar, van, M.W., Cruts, A.A.N., van Ooyen-Houben, M.M.J., Meijer, R.F., &

Brunt T.M. (2011). The Netherlands National Drug Monitor: Annual

Report 2010. Trimbos Institute, Utrecht, The Netherlands.

Ladroue, C., Guo, S., Kendrick, K., Feng, J. (2009). Beyond element-wise

interactions: identifying complex interactions in biological processes.

PLoS One. 4, e6899

Lange, R.A., Hillis, L.D. (2001). Cardiovascular complications of cocaine

use. N. Engl. J. Med. 345, 351-358

Legleye S, Ben Lakhdar C, Spilka S.(2008). Two ways of estimating the

euro value of the illicit market for cannabis in France. Drug Alcohol

Rev. 27(5), 466-472

Leikin, J.B., Morris, R.W., Warren, M., Erickson, T. (2001). Trends in a

decade of drug abuse presentation to an inner city ED. Am. J.

Emerg. Med. 19, 37-39.

Liechti ME, Gamma A, Vollenweider FX. (2001). Gender differences in the

subjective effects of MDMA. Psychopharmacology Berl 154, 161-

168

Liechti ME, Vollenweider FX. (2001). Which neuroreceptors mediate the

subjective effects of MDMA in humans? A summary of mechanistic

studies. Hum. Psychopharmacology 16(8), 589-598

Lin DL, Liu HC, Yin HL. (2007). Recent paramethoxymethamphetamine

(PMMA) deaths in Taiwan. J. Anal. Toxicol. 31, 109-113

Lin JC, Bangs N, Lee H, Kydd RR, Russell BR. (2009). Determining the

subjective and physiological effects of BZP on human females.

Psychopharmacology Berl 207, 439-446

Lin JC, Jan RK, Lee H, Jensen MA, Kydd RR, Russell BR. (2011).

Determining the subjective and physiological effects of BZP

combined with TFMPP in human males. Psychopharmacology Berl

214, 761-768

191

Lora-Tamayo C, Tena T, Rodríguez A, Moreno D, Sancho JR, Enseñat P,

Muela F. (2004). The designer drug situation in Ibiza. Forensic Sci.

Int. 140, 195-206

Llorca P.M., Spadone C., Sol O., Danniau A., Bougerol T., Corruble E. et

al. (2002). Efficacy and safety of hydroxyzine in the treatment of

generalized anxiety disorder: a 3-month double-blind study. J Clin

Psychiatry 63, 1020-1027

Lütkepohl, H. (2006). New Introduction to Multiple Time Series Analysis,

1st ed. Springer-Verlag, New York, United States

Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE. (1995).

Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur.

J. Pharmacol. 287, 105-113

Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. (2009).

The safety of metoclopramide use in the first trimester of pregnancy.

N. Engl. J. Med. 360, 2528-2535

Matthews A, Bruno R, Johnston J, Black E, Degenhardt L, Dunn M. (2009).

Factors associated with driving under the influence of alcohol and

drugs among an Australian sample of regular ecstasy users. Drug

Alcohol Dependence 100(1-2), 24-31

Maurer HH, Kraemer T, Springer D, Staack RF. (2004). Chemistry,

pharmacology, toxicology, and hepatic metabolism of designer drugs

of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone

types: a synopsis. Ther. Drug Monit. 26, 127-131

McCance-Katz, E.F., Kosten, T.R., Jatlow, P. (1998). Concurrent use of

cocaine and alcohol is more potent and potentially more toxic than

use of either alone--a multiple-dose study. Biol. Psychiatry 44, 250-

259

McCann UD, Ridenour A, Shaham Y, Ricaurte GA. (1994). Serotonin

neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine

(MDMA; "Ecstasy"): a controlled study in humans.

Neuropsychopharmacology 10(2), 129-138

McCann, UD, Wong, DF, Yokoi, F, Villemagne, V, Dannals, RF, Ricaurte,

GA. (1998). Reduced striatal dopamine transporter density in

abstinent methamphetamine and methcathinone users: evidence

192

from positron emission tomography studies with [11C]WIN-35,428. J.

Neurosci. 18, 8417-22.

McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. (1998).

Positron emission tomographic evidence of toxic effect of MDMA

("Ecstasy") on brain serotonin neurons in human beings. Lancet

352(9138), 1433-1437

McCann UD, Eligulashvili V, Ricaurte GA. (2000). (+/-)3,4-

Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin

neurotoxicity: clinical studies. Neuropsychobiology 42(1), 11-16

McCann, U.D., Ricaurte, G.A. (2004). Amphetamine neurotoxicity:

accomplishments and remaining challenges. Neurosci. Biobehav.

Rev. 27, 821-826

McCleary, R., & Hay, R.A. (1980). Applied Time Series Analysis for the

Social Sciences. Sage Publications, Beverly Hills, CA

McElrath K, O'Neill C. (2011). Experiences with mephedrone pre- and

post-legislative controls: perceptions of safety and sources of supply.

Int. J. Drug Policy 22, 120-127

McKinney C.D., Postiglione K.F., Herold D.A. (1992). Benzocaine-

adultered street cocaine in association with methemoglobinemia.

Clin. Chem. 38, 596-597

McTavish J.R. (2004). Pain and Profits: The History of the Headache and

Its Remedies in America. 2 ed. New Brunswick, NJ: Rutgers

University Press

Measham, F, Moore, K, Newcombe, R, Welch, Z. (2010). „Tweaking,

Bombing, Dabbing and Stockpiling: The emergence of mephedrone

and the perversity of prohibition‟. Drugs and Alcohol Today 10, 14-

21.

Medina, K.L., & Shear, P.K. (2007). Anxiety, depression, and behavioral

symptoms of executive dysfunction in ecstasy users: contributions of

polydrug use. Drug and Alcohol Dependence 87, 303-311

Mensink, C. & Spruit, I.P. (1999). Jaarboek Verslaving 1998. Bohn Stafleu

Van Loghum, Houten/Diegem.

193

Miksys S., Tyndale R.F. (2004). The unique regulation of brain cytochrome

P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab.

Rev. 36, 313-33

Milhazes, N., Martins, P., Uriarte, E., Garrido, J., Calheiros, R., Marques,

M.P., & Borges, F. (2007). Electrochemical and spectroscopic

characterisation of amphetamine-like drugs: application to the

screening of 3,4-methylenedioxymethamphetamine (MDMA) and its

synthetic precursors. Analytica Chimica Acta 596(2), 231-241

Milliet, Q., Weyermann, C., & Esseiva, P. (2009). The profiling of MDMA

tablets: a study of the combination of physical characteristics and

organic impurities as sources of information. Forensic Sci. Int. 187(1-

3), 58-65

Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. (2011). The

safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-

assisted psychotherapy in subjects with chronic, treatment-resistant

posttraumatic stress disorder: the first randomized controlled pilot

study. J. Psychopharmacology 25(4), 439-452

Morefield KM, Keane M, Felgate P, White JM, Irvine RJ. (2011). Pill

content, dose and resulting plasma concentrations of 3,4-

methylendioxymethamphetamine (MDMA) in recreational 'ecstasy'

users Addiction 106, 1293-1300

Morgan CJA, Muetzelfeldt L, Muetzelfeldt M, Nutt DJ, Curran HV. (2010).

Harms associated with psychoactive substances: findings of the UK

National Drug Survey. J. Psychopharmacology 24(2), 147-153

Morris K. (2010). UK places generic ban on mephedrone drug family.

Lancet 375, 1333-1334

Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS. (2011).

Mephedrone (4-Methylmethcathinone, “Meow”): Acute Behavioural

Effects and Distribution of Fos Expression in Adolescent Rats. Add.

Biol. In press

Mounteney J, Haugland S. (2009). Earlier warning: a multi-indicator

approach to monitoring of trends in the illicit use of medicines. Int. J.

Drug Policy 20, 161–169

194

Murphy PN, Wareing M, Fisk J (2006) Users' perceptions of the risks and

effects of taking ecstasy (MDMA): a questionnaire study. J.

Psychopharmacology 20, 447-455

Nabben, T. (2010). High Amsterdam. Ritme, roes en regels in het

uitgaansleven. Candide, Amsterdam

Nagai F, Nonaka R, Satoh Hisashi Kamimura K. (2007). The effects of

non-medically used psychoactive drugs on monoamine

neurotransmission in rat brain. Eur. J. Pharmacol. 559, 132-137

Newcombe, R (2009) The use of Mephedrone (MCAT, Meow) in

Middlesbrough. Lifeline Publications and Research: Manchester.

Available at: http://www.lifeline.org.uk/docs/M-cat%20report%

20small.pdf

Nichols DE. (1986). Differences between the mechanism of action of

MDMA, MBDB, and the classic hallucinogens. Identification of a new

therapeutic class: entactogens. J. Psychoactive Drugs 18(4), 305-

313

Nichols D. (2011). Legal highs: the dark side of medicinal chemistry.

Nature 469(7328), 7

Niemann A. (1860). Ueber eine neue organische Base in den Cocablättern.

Archiv der Pharmazie 153 (2), 129–256

Nolte K.B. (1991). Rhabdomyolysis associated with cocaine abuse. Hum.

Pathol. 22, 1141-1145

Nutt, D., King, L.A., Saulsbury, W., Blakemore, C. (2007). Development of

a rational scale to assess the harm of drugs of potential misuse.

Lancet 369(9566), 1047-1053

Nutt, D.J., King, L.A., & Phillips, L.D; Independent Scientific Committee on

Drugs. (2010). Drug harms in the UK: a multicriteria decision

analysis. Lancet 376(9752), 1558-1565

Nuijs van, et al. (2009). Cocaine and metabolites in waste and surface

water across Belgium. Environ. Pol. 157(1), 123-129

Pai, S.A., Lakshmi, P.K., Rao, B.C., Sahni, P. (2003). Pharmaceutical

companies and the third world. Lancet 361, 1136-1137.

Páleníček T, Balíková M, Rohanová M, Novák T, Horáček J, Fujáková M,

Höschl C. (2011). Behavioral, hyperthermic and pharmacokinetic

195

profile of para-methoxymethamphetamine (PMMA) in rats.

Pharmacol. Biochem. Behav. 98, 130-139

de Paoli G, Brandt SD, Pounder DJ. (2011). Mephedrone. Banned but still

available on the internet. BMJ. 342, d1629

Parker H.J., Aldridge J., Measham F. (1998). Illegal leisure: the

normalization of adolescent recreational drug use. Routledge,

London

Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J.

(2002). Ecstasy/MDMA attributed problems reported by novice,

moderate and heavy recreational users. Hum. Psychopharmacology

17, 309-312

Parrott AC. (2004a). MDMA (3,4-Methylenedioxymethamphetamine) or

ecstasy: the neuropsychobiological implications of taking it at dances

and raves. Neuropsychobiology 50(4), 329-335

Parrott AC. (2004b). Is ecstasy MDMA? A review of the proportion of

ecstasy tablets containing MDMA, their dosage levels, and the

changing perceptions of purity. Psychopharmacology Berl 173:234-

241

Parrott AC. (2006). MDMA in humans: factors which affect the

neuropsychobiological profiles of recreational ecstasy users, the

integrative role of bioenergetic stress. J. Psychopharmacology 20,

147-163

Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB.

(2006). Dancing hot on Ecstasy: physical activity and thermal

comfort ratings are associated with the memory and other

psychobiological problems reported by recreational MDMA users.

Hum. Psychopharmacology 21, 285-298

Parrott, A.C., Milani, R., Parmar, R., & Turner, J.J.D. (2001). Ecstasy

polydrug users and other recreational drug users in Britain and Italy:

psychiatric symptoms and psychobiological problems.

Psychopharmacology Berl 159(1), 77–82.

Pennings, E.J., Leccese, A.P., Wolff, F.A. (2002). Effects of concurrent use

of alcohol and cocaine. Addiction 97, 773-783

196

Peroutka SJ, Newman H, Harris H. (1988). Subjective effects of 3,4-

methylenedioxymethamphetamine in recreational users.

Neuropsychopharmacology 1, 273-277

Peters J.M., Morishima H., Ward J.M., Coakley C.J., Kimura S., Gonzalez

F.J. (1999). Role of CYP1A2 in the toxicity of long-term phenacetin

feeding in mice. Toxicol. Sci. 50, 82-9

Peterson, B.S., Potenza, M.N., Wang, Z., Zhu, H., Martin, A., Marsh, R.,

Plessen, K.J., Yu, S. (2009) An FMRI study of the effects of

psychostimulants on default-mode processing during Stroop task

performance in youths with ADHD. Am. J. Psychiatry 166, 1286-1294

Pozner C.N., Levine M., Zane R. (2005). The cardiovascular effects of

cocaine. J. Emerg. Med. 29, 173-178

Punukollu G., Gowda R.M., Khan I.A., Dogan O.M. (2003). Delayed

presentation of calcium channel antagonist overdose. Am. J. Ther.

10, 132-134

Pijlman, FT, Krul, J, Niesink, RJ. (2003). Uitgaan en veiligheid. Trimbos-

instituut, Utrecht

Pijlman, F.T.A., Rigter, S., Hoek J., & Niesink, R. (2005). Increased levels

of total THC in cannabis sold in Dutch coffee shops. Addict. Biol.

10(2), 171-180

Ramsey, J.D., Butcher, M.A., Murphy, M.F., Lee, T., Johnston, A., Holt,

D.W. (2001). A new method to monitor drugs at dance venues. BMJ.

323, 603

Rasmussen N. (2009). On Speed: The Many Lives of Amphetamine. NYU

Press, New York

Refstad S. (2003). Paramethoxyamphetamine (PMA) poisoning; a 'party

drug' with lethal effects. Acta Anaesthesiol. Scand. 47(10), 1298-

1299

Rendic S. (2002). Summary of information on human CYP enzymes:

human P450 metabolism data. Drug Metab. Rev. 34, 83-448.

Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB,

den Heeten GJ, van den Brink W. (2001). Effects of dose, sex, and

long-term abstention from use on toxic effects of MDMA (ecstasy) on

brain serotonin neurons. Lancet 358(9296):1864-1869

197

Reynolds S. (1999). Generation Ecstasy : Into the World of Techno and

Rave Culture. Routledge, New York

Ricaurte GA, McCann UD, Szabo Z, Scheffel U. (2000). Toxicodynamics

and long-term toxicity of the recreational drug, 3, 4-

methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol. Lett.

112-113, 143-146

Riedlinger TJ, Riedlinger JE. (1994). Psychedelic and entactogenic drugs

in the treatment of depression. J Psychoactive Drugs 26(1), 41-55

Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. (1987). Cocaine receptors on

dopamine transporters are related to self-administration of cocaine.

Science 237(4819),1219-1223

Rodenburg G, Spijkerman R, van den Eijnden R, van de Mheen D.

National prevalence research substance abuse 2005. (2007). IVO,

Rotterdam. Available at:

http://www.hetccv.nl/binaries/ccv/dossiers/bestuurlijkhandhaven/drug

sbeleid/cannabis/nationaal_onderzoek_middelengebruik.pdf

Rohanova M, Balikova M. (2009). Studies on distribution and metabolism

of para-methoxymethamphetamine (PMMA) in rats after

subcutaneous administration. Toxicology 259, 61-68

Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI,

Partilla JS. (2001). Amphetamine-type central nervous system

stimulants release norepinephrine more potently than they release

dopamine and serotonin. Synapse 39, 32-41

Rothman, RB, Blough, BE, Baumann, MH. (2008). Dual

Dopamine/Serotonin Releasers as Potential Medications for

Stimulant and Alcohol Addictions In: Drug Addiction. Papaka RS,

Sadée W (eds). Springer: New York. pp 311-326.

Rowbotham M.C., Hooker W.D., Mendelson J., Jones R.T. (1987).

Cocaine-calcium channel antagonist interactions.

Psychopharmacology (Berl) 93, 152-154.

Roxburgh, A., Degenhardt, L., & Breen, C. (2004). Changes in patterns of

drug use among injecting drug users following changes in the

availability of heroin in New South Wales, Australia. Drug and

Alcohol Rev. 23(3), 287-294.

198

Rudnick G, Wall SC. (1992). The molecular mechanism of "ecstasy" [3,4-

methylenedioxy-methamphetamine (MDMA)]: serotonin transporters

are targets for MDMA-induced serotonin release. Proc. Natl. Acad.

Sci. U S A. 89(5), 1817-1821

Saunders N, Shulgin A. (1993). E for Ecstasy. 14 Neal's Yard, London

Segen J. (2002). Dictionary of Modern Medicine 2nd ed. McGraw-Hill, New

York

Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH. (2003a). Death

rates from ecstasy (MDMA, MDA) and polydrug use in England and

Wales 1996-2002 Hum. Psychopharmacology 18(7), 519-524

Schifano, F, Leoni, M, Martinotti, G, Rawaf, S, Rovetto, F. (2003b).

Importance of cyberspace for the assessment of the drug abuse

market: preliminary results from the Psychonaut 2002 project.

Cyberpsychol. Behav. 6, 405-410

Schifano F, Deluca P, Baldacchino A, Peltoniemi T, Scherbaum N, Torrens

M, et al. (2006a). The Psychonaut 2002 EU project. Prog.

Neuropsychopharmacology Biol. Psychiatry 30, 640–646

Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH. (2006b). Ecstasy

(MDMA, MDA, MDEA, MBDB) consumption, seizures, related

offences, prices, dosage levels and deaths in the UK (1994-2003).

J. Psychopharmacology 20, 456-463

Schifano, F., Corkery, J. (2008). Cocaine/crack cocaine consumption,

addiction treatment demand, seizures, related offences, prices,

average purity levels and deaths in the UK (1990 - 2004). J.

Psychopharmacol. 22, 71-79

Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, Davey

Z, Corkery J, Siemann H, Scherbaum N, Farré M, Torrens M,

Demetrovics Z, Ghodse AH; Psychonaut Web Mapping; ReDNet

Research Groups. (2011). Mephedrone (4-methylmethcathinone;

'meow meow'): chemical, pharmacological and clinical issues.

Psychopharmacology Berl 214, 593-602

Schindler C.W., Tella S.R., Erzouki H.K., Goldberg S.R. (1995).

Pharmacological mechanisms in cocaine's cardiovascular effects.

Drug Alcohol Dependence 37, 183-191

199

Shadish, W.R., Cook, T.D., & Campbell, D.T. (2002). Experimental and

Quasi-Experimental Designs for Generalized Causal Inference.

Houghton Mifflin, Boston, MA

Shao B, Chen D, Zhang J, Wu NY and Sun CJ. (2009). Determination of

76 pharmaceutical drugs by liquid chromatography-tandem mass

spectrometry in slaughterhouse wastewater. J. Chromatogr. A.

1216(47), 8312-8318

Sharkey J., Ritz M.C., Schenden J.A., Hanson R.C., Kuhar M.J. (1988).

Cocaine inhibits muscarinic cholinergic receptors in heart and brain.

J. Pharmacol. Exp. Ther. 246, 1048-1052

Sharma S.P., Purkait B.C., Lahiri S.C. (2005). Qualitative and quantitative

analysis of seized street drug samples and identification of source.

Forensic Sci. Int. 152(2-3), 235-240

Shearer, J., Gowing, L.R. (2004). Pharmacotherapies for problematic

psychostimulant use: a review of current research. Drug Alcohol Rev.

23, 203-211

Sikk, K, Taba, P, Haldre, S, Bergquist, J, Nyholm, D, Zjablov, G, et al.

(2007). Irreversible motor impairment in young addicts-ephedrone,

manganism or both? Acta Neurol Scand 115: 385-389.

Simonsen KW, Kaa E, Nielsen E, Rollmann D. (2003). Narcotics at street

level in Denmark. A prospective investigation from 1995 to 2000.

Forensic Sci. Int. 131, 162-170

Smithson, M., McFadden, M., & Mwesigye, S.E. (2005). Impact of Federal

drug law enforcement on the supply of heroin in Australia. Addiction

100(8), 1110-1120.

Smithson, M., McFadden, M., Mwesigye, S.E., Casey, T. (2004). The

impact of illicit drug supply reduction on health and social outcomes:

the heroin shortage in the Australian Capital Territory. Addiction 99,

340-348.

Sparago, M, Wlos, J, Yuan, J, Hatzidimitriou, G, Tolliver, J, Dal Cason, TA,

et al. (1996). Neurotoxic and pharmacologic studies on enantiomers

of the N-methylated analog of cathinone (methcathinone): a new

drug of abuse. J. Pharmacol. Exp. Ther. 279, 1043-1052.

200

Spruit, I.P. (1999). Ecstasy use and policy responses in the Netherlands.

Journal of Drug Issues 29, 653-678.

Spruit, I.P. (2001). Monitoring synthetic drug markets, trends, and public

health. Substance Use and Misuse 36(1-2), 23–47

Staack RF, Maurer HH. (2003). Piperazine-derived designer drug 1-(3-

chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism

and its toxicological detection in rat urine including analytical

differentiation from its precursor drugs trazodone and nefazodone. J.

Anal. Toxicol. 27, 560-568

Staack R.F., Paul L.D., Schmid D., Roider G., Rolf B. (2007). Proof of a 1-

(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of

cocaine resulting in drug-drug interactions? J Chromatogr B Analyt

Technol Biomed Life Sci 855, 127-33.

Staack RF. (2007). Piperazine designer drugs of abuse. Lancet 369, 1411-

1413

Stepens, A, Logina, I, Liguts, V, Aldins, P, Eksteina, I, Platkājis, A, et al.

(2008). A Parkinsonian syndrome in methcathinone users and the

role of manganese. N. Engl. J. Med. 358, 1009-17.

Sulzer D, Sonders MS, Poulsen NW, Galli A. (2005). Mechanisms of

neurotransmitter release by amphetamines: a review. Prog.

Neurobiol. 75(6), 406-433

Sumnall, H. R., Tyler, E., Wagstaff, G. F., & Cole, J.C.A. (2004).

Behavioural economic analysis of alcohol, amphetamine, cocaine

and ecstasy purchases by polysubstance misusers. Drug and

Alcohol Dependence 76(1), 93-99.

Sumnall HR, Cole JC, Jerome L. (2006). The varieties of ecstatic

experience: an exploration of the subjective experiences of ecstasy.

J. Psychopharmacology 20, 670-682

Sweetman S.C., editor. Martindale: The Complete Drug Reference. 35 ed.

London: Pharmaceutical Press; 2006.

Tancer ME, Johanson CE. (2001). The subjective effects of MDMA and

mCPP in moderate MDMA users. Drug. Alcohol Dependence 65, 97-

101

201

Tancer M, Johanson CE. (2003). Reinforcing, subjective, and physiological

effects of MDMA in humans: a comparison with d-amphetamine and

mCPP. Drug Alcohol Dependence 72, 33-44

Tanner-Smith EE. (2006). Pharmacological content of tablets sold as

"ecstasy": results from an online testing service. Drug Alcohol

Dependence 83, 247-254

Taylor, W. (2000). A Pattern Test for Distinguishing Between

Autoregressive and Mean-Shift Data. Available at:

http://www.variation.com/cpa/tech/pattern.html

Teng SF, Wu SC, Liu C, Li JH, Chien CS. (2006). Characteristics and

trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets

found in Taiwan from 2002 to February 2005. Forensic Sci. Int.

161(2-3), 202-208

Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P,

Wartberg L, Nebeling B, Schmoldt A. (2003). Mood, cognition and

serotonin transporter availability in current and former ecstasy

(MDMA) users. Psychopharmacology Berl 167, 85-96

Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. (2007).

A role for oxytocin and 5-HT(1A) receptors in the prosocial effects

of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience

146(2), 509-514

Topp, L., Day, C., & Degenhardt, L. (2003). Changes in patterns of drug

injection concurrent with a sustained reduction in the availability of

heroin in Australia. Drug and Alcohol Dependence 70(3), 275-286.

de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M,

Segura J, Camí J. (2004). Human pharmacology of MDMA:

pharmacokinetics, metabolism, and disposition. Ther. Drug Monit.

26(2), 137-144

Toumbourou JW, Stockwell T, Neighbors C, Marlatt GA, Sturge J, Rehm J.

(2007). Interventions to reduce harm associated with adolescent

substance use. Lancet 369, 1391-1401

Uhl GR, Hall FS, Sora I. (2002). Cocaine, reward, movement and

monoamine transporters. Mol. Psychiatry 7(1), 21-6

202

United Nations Office on Drugs and Crime (UNODC). (2011). World Drug

Report 2011.http://www.unodc.org/documents/data-and-

analysis/WDR2011/World_Drug_Report_2011_ebook.pdf

UNODC. (2008). Amphetamines and Ecstasy.http://www.unodc.org/

documents/scientific/ATS/Global-ATS-Assessment-2008-Web.pdf

UNODC. (2010). United Nations Office on Drugs and Crime, World Drug

Report 2010, http://www.unodc.org/documents/wdr/WDR_2010/

World_Drug_Report_2010_lo-res.pdf

United Nations Office on Drugs and Crime (UNODC). (2008). World Drug

Report 2008. Vienna, United Nations. Available at:

http://www.unodc.org/documents/wdr/WDR_2008/WDR_2008_eng_

web.pdf

United Nations Office on Drugs and Crime. (2007). World Drug Report

2007. Available at http://www.unodc.org/pdf/research/wdr07/

WDR_2007.pdf

United States Drug Enforcement Administration. (2010). Cocaine.

http://www.justice.gov/ndic/pubs31/31379/cocaine.htm#Figure3

United States Drug Enforcement Administration. (2010). Microgram

Bulletins.

http://www.justice.gov/dea/programs/forensicsci/microgram/bulletins_

index.html

Varlibas, F, Delipoyraz, I, Yuksel, G, Filiz, G, Tireli, H, Gecim, NO. (2009).

Neurotoxicity following chronic intravenous use of “Russian cocktail”.

Clin Toxicol 47, 157-60

Verheyden SL, Hadfield J, Calin T, Curran HV. (2002). Sub-acute effects of

MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on

mood: evidence of gender differences. Psychopharmacology Berl

161, 23-31

Vitale, S., van de Mheen, D. (2006). Illicit drug use and injuries: A review of

emergency room studies. Drug Alcohol Dependence 82, 1-9.

Vogels, N., Brunt, T.M., Rigter, S., Van Dijk, P., Vervaeke, H., Niesink,

R.J.M. (2009). Content of ecstasy in the Netherlands: 1993-2008.

Addiction 104, 2057-2066

203

Weatherburn, D., Jones, C., Freeman, K., & Makkai, T. (2003). Supply

control and harm reduction: lessons from the Australian heroin

'drought'. Addiction 98(1), 83-91.

Weatherburn, D. (2009). Dilemmas in harm minimization. Addiction 104(3),

335-339.

Weber, J.E., Chudnofsky, C.R., Boczar, M., Boyer, E.W., Wilkerson, M.D.,

Hollander, J.E. (2000). Cocaine-associated chest pain: how common

is myocardial infarction? Acad Emerg. Med. 7, 873-877.

Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE,

Woolverton WL. (2005). Relationship between the serotonergic

activity and reinforcing effects of a series of amphetamine analogs. J.

Pharmacol. Exp. Ther. 313, 848-854

Weiner A.L., Bayer M.J., McKay C.A., Jr., DeMeo M., Starr E. (1998).

Anticholinergic poisoning with adulterated intranasal cocaine. Am .J.

Emerg. Med. 16, 517-20.

Westover, A.N., McBride, S., Haley, R.W. (2007). Stroke in young adults

who abuse amphetamines or cocaine: a population-based study of

hospitalized patients. Arch. Gen. Psychiatry 64, 495-502.

Williams, J., Pacula, R.L., Chaloupka, F.J., Wechsler, H. (2006). College

students' use of cocaine. Subst. Use Misuse 41, 489-509.

de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga

SD, den Heeten GJ, van den Brink W. (2008). Sustained effects of

ecstasy on the human brain: a prospective neuroimaging study in

novel users. Brain 131(Pt 11), 2936-2945

Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F.

(2011). Mephedrone, new kid for the chop? Addiction 106, 154-161

Wodak, A (2008) What caused the recent reduction in heroin supply in

Australia? Int. J. Drug Policy 19, 279-286.

Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML,

Aitchison KJ. (2006). Vasopressin and oxytocin secretion in response

to the consumption of ecstasy in a clubbing population. J.

Psychopharmacology 20(3), 400-410

204

Wood, E., Stoltz, J., Li, K., Montaner, J. & Kerr, T. (2006). Changes in

Canadian heroin supply coinciding with the Australian heroin

shortage. Addiction, 101(5), 689-695.

Wu, L.T., Parrott, A.C., Ringwalt, C.L., Yang, C., & Blazer, D.G. (2009).

The variety of ecstasy/MDMA users: results from the National

Epidemiologic Survey on alcohol and related conditions. The

American Journal on Addictions 18(6), 452-461.

Zuccato, E., Chiabrando, C., Castiglioni, S., Bagnati, R., Fanelli, R. (2008).

Estimating community drug abuse by wastewater analysis. Environ.

Health Persp. 116(8), 1027-1032